Series C · Biotech · Barcelona, Spain · Founded 2011 · 11–50 employees
Minoryx Therapeutics is a late-stage biotech company focused on developing novel treatments for severe, orphan diseases of the central nervous system. Their lead compound leriglitazone (MIN-102) is a brain-penetrant PPAR gamma agonist in Phase 3 clinical trials for X-linked Adrenoleukodystrophy and other rare CNS diseases. The company has raised over €120 million to date including a €51 million Series C round in 2022 and recently received a €26.9 million EU grant. Their drug candidate has shown promising clinical results in pivotal trials, positioning them as a potential breakthrough therapy for devastating neurological conditions with no current treatment options.
No open roles listed right now.